Drug-Coated Balloons versus Everolimus-Eluting Stents in Patients with In-Stent Restenosis: A Pair-Wise Meta-Analysis of Randomized Trials

Drug-Coated Balloons versus Everolimus-Eluting Stents in Patients with In-Stent Restenosis: A Pair-Wise Meta-Analysis of Randomized Trials

Objective. This study aimed to compare the effectiveness of drug-coated balloons (DCB) with everolimus-eluting stents (EES) in the treatment of in-stent restenosis (ISR) and the differential relative effect of DCB in patients with drug-eluting stents (DES)-ISR and bare metal stents (BMS)-ISR. Backgr...

Full description

Bibliographic Details
Main Authors:	Nina Peng, Wei Liu, Zongzhuang Li, Jun Wei, Xuejun Chen, Wei Wang, Hao Lin
Format:	Article
Language:	English
Published:	Hindawi-Wiley 2020-01-01
Series:	Cardiovascular Therapeutics
Online Access:	http://dx.doi.org/10.1155/2020/1042329

Similar Items

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
by: Hang Ouyang, et al.
Published: (2021-04-01)

Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis: An Updated Systematic Review and Meta-Analysis
by: Kong-Yong Cui, et al.
Published: (2018-01-01)

Drug-eluting stents or balloon angioplasty for drug-eluting stent-associated restenosis: An observational follow-up study of first-time versus repeated restenosis
by: Mohamed Aboel-Kassem F. Abdelmegid, et al.
Published: (2017-04-01)

Clinical Outcomes of Drug-Eluting versus Bare-Metal In-Stent Restenosis after the Treatment of Drug-Eluting Stent or Drug-Eluting Balloon: A Systematic Review and Meta-Analysis
by: Yi-Xing Yang, et al.
Published: (2020-01-01)

Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis
by: Wen-Juan Xiu, et al.
Published: (2018-01-01)

Impact of the distance from the stent edge to the residual plaque on edge restenosis following everolimus-eluting stent implantation.
by: Masao Takahashi, et al.
Published: (2015-01-01)

Everolimus-eluting coronary stents
by: Alejandro Saez, et al.
Published: (2010-09-01)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug- Eluting Stents
by: Negar Faramarzi, et al.
Published: (2015-10-01)

Stent Fracture after Everolimus-Eluting Stent Implantation
by: Ali S. Almasood, et al.
Published: (2011-01-01)

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
by: Nisha Ohri, MD, et al.
Published: (2016-01-01)

Everolimus-eluting stents in interventional cardiology
by: Townsend JC, et al.
Published: (2012-06-01)

Twelve-month comparative analysis of clinical outcomes using biodegradable polymer–coated everolimus-eluting stents versus durable polymer–coated everolimus-eluting stents in all-comer patients
by: Atul Abhyankar, et al.
Published: (2019-03-01)

Drug-eluting stent in-stent restenosis and re-restenosis: A hard time story
by: Violeta Dinesch, et al.
Published: (2017-04-01)

Study to assess clinical outcomes of an everolimus-eluting stent (EES) versus a sirolimus-eluting stent (SES)
by: Amit Madaan, et al.
Published: (2015-12-01)

Paclitaxel-eluting stent (PES) versus everolimus-eluting stent (EES) in insulin requiring diabetics – Are the results different?
by: U. Kaul, et al.
Published: (2015-12-01)

Two-year results of an open-label randomized comparison of everolimus-eluting stents and sirolimus-eluting stents.
by: Matthijs A Velders, et al.
Published: (2014-01-01)

Response to drug-eluting stent in-stent restenosis and re-restenosis: A hard time story
Published: (2017-04-01)

Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population
by: Guillaume Marquis-Gravel, et al.
Published: (2017-09-01)

Comparison of clinical outcomes after drug-eluting balloon and drug-eluting stent use for in-stent restenosis related acute myocardial infarction: a retrospective study
by: Chih-Yuan Fang, et al.
Published: (2018-04-01)

One-Year Outcome of Everolimus-Eluting Stents versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
by: Mohammad Alidoosti, et al.
Published: (2016-10-01)

Overview of intracoronary brachytherapy for in-stent restenosis of a drug-eluting stent
by: Sohila Refahi, et al.
Published: (2019-03-01)

Correction: Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
by: Matthijs A. Velders, et al.
Published: (2013-01-01)

Correction: Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents.
by: Matthijs A. Velders, et al.
Published: (2013-01-01)

Cutting balloon versus conventional angioplasty for the treatment of in-stent restenosis
by: Shu-Lin Chang, et al.
Published: (2008)

Clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents versus durable polymer everolimus-eluting Xience stents.
by: Da Hyon Lee, et al.
Published: (2017-01-01)

Genetic risk model for in-stent restenosis of second-and third-generation drug-eluting stents
by: Yen-Wen Liu, et al.
Published: (2021-09-01)

miR-22 eluting cardiovascular stent based on a self-healable spongy coating inhibits in-stent restenosis
by: Jing Wang, et al.
Published: (2021-12-01)

Everolimus-eluting stents: update on current clinical studies
by: Allocco DJ, et al.
Published: (2011-07-01)

Risk assessment score for drug eluting stent restenosis
by: Z. A. Gabbasov, et al.
Published: (2018-09-01)

Comparison of the efficacy of drug-eluting balloon for de novo lesions and in-stent restenosis lesions of the femoropopliteal arteries
by: Yuefeng Zhu, et al.
Published: (2019-09-01)

Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis
by: Leos Pleva, et al.
Published: (2017-06-01)

Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes
by: Ryota Kakizaki, et al.
Published: (2020-10-01)

The Twelve-Month Outcome of Biolimus Eluting Stent with Biodegradable Polymer Compared With an Everolimus Eluting Stent with Durable Polymer
by: Ahmad Separham, et al.
Published: (2011-11-01)

Comparison of Bare metal Vs Drug eluting stents for in-stent Restenosis among Diabetics
by: Kakhaber Etsadashvili, et al.
Published: (2011-06-01)

Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform
by: Matthew G. Whitbeck, et al.
Published: (2013-07-01)

Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform
by: Matthew G. Whitbeck, et al.
Published: (2013-01-01)

Outcomes of patients treated with the everolimus-eluting stent versus the zotarolimus-eluting stent in a consecutive cohort of patients at a tertiary medical center
by: Jerin M, et al.
Published: (2012-04-01)

Effect of pioglitazone on in-stent restenosis after coronary drug-eluting stent implantation: a meta-analysis of randomized controlled trials.
by: Ming-duo Zhang, et al.
Published: (2014-01-01)

Long-term efficacy of drug-coated balloon for renal artery in-stent restenosis
by: Mostafa Elwany, et al.
Published: (2018-03-01)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®)
by: Imad Sheiban, et al.
Published: (2008-02-01)